{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:32:57Z","timestamp":1793709177189,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100020737","name":"Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital","doi-asserted-by":"publisher","award":["PYII20-11"],"award-info":[{"award-number":["PYII20-11"]}],"id":[{"id":"10.13039\/501100020737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173826"],"award-info":[{"award-number":["82173826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.eururo.2022.05.029","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:53:13Z","timestamp":1655254393000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma"],"prefix":"10.1016","volume":"83","author":[{"given":"Yunze","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baijun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochuan","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengcheng","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.05.029_b0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/jmg.2010.085068","article-title":"Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma","volume":"48","author":"Gardie","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.eururo.2022.05.029_b0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","article-title":"A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients","volume":"44","author":"Lau","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2022.05.029_b0015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.05.029_b0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2013part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.05.029_b0025","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/PAS.0000000000000617","article-title":"Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome","volume":"40","author":"Trpkov","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2022.05.029_b0030","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.5858\/arpa.2018-0216-RA","article-title":"Hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC): a contemporary review and practical discussion of the differential diagnosis for HLRCC-associated renal cell carcinoma","volume":"142","author":"Skala","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.eururo.2022.05.029_b0035","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Kidney cancer (version 2. 2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"10.1016\/j.eururo.2022.05.029_b0040","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.6004\/jnccn.2020.0043","article-title":"NCCN guidelines insights: kidney cancer, version 1.2021","volume":"18","author":"Motzer","year":"2020","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.eururo.2022.05.029_b0045","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/RLU.0000000000000875","article-title":"Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET\/CT","volume":"40","author":"Takahashi","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2022.05.029_b0050","first-page":"383","article-title":"Clinical evaluation of 2-(18F)-fluoro-2 deoxy-D-glucose PET\/ CT in hereditary leiomyomatosis and renal cell carcinoma","volume":"31","author":"Schuh","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.05.029_b0055","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2018.04.009","article-title":"Re: Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling","volume":"74","author":"Xu","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.05.029_b0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.05.029_b0065","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumor imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2022.05.029_b0070","doi-asserted-by":"crossref","first-page":"151599","DOI":"10.1016\/j.anndiagpath.2020.151599","article-title":"Fumarate hydratase-deficient renal cell carcinoma: a clinicopathological study of seven cases including hereditary and sporadic forms","volume":"49","author":"Kuroda","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.eururo.2022.05.029_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2022.05.029_b0080","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/PAS.0000000000000719","article-title":"Tubulocystic carcinoma of the kidney with poorly differentiated foci: a frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma","volume":"40","author":"Smith","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2022.05.029_b0085","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10689-014-9735-2","article-title":"Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment","volume":"13","author":"Menko","year":"2014","journal-title":"Fam Cancer"},{"key":"10.1016\/j.eururo.2022.05.029_b0090","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/cncr.32914","article-title":"Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer","volume":"126","author":"Shuch","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.05.029_b0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/his.13183","article-title":"A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma","volume":"71","author":"Smith","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.eururo.2022.05.029_b0100","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ccr.2011.07.018","article-title":"The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels","volume":"20","author":"Tong","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2022.05.029_b0105","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","article-title":"Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Sun","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.05.029_b0110","doi-asserted-by":"crossref","first-page":"13131","DOI":"10.1038\/ncomms13131","article-title":"Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets","volume":"7","author":"Chen","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2022.05.029_b0115","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2022.05.029_b0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrurol.2010.234","article-title":"Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCC","volume":"8","author":"Yamasaki","year":"2011","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2022.05.029_b0125","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1097\/RLU.0000000000001612","article-title":"Prognostic value of pretreatment metabolic tumor volume and total lesion glycolysis using 18F-FDG PET\/CT in patients with metastatic renal cell carcinoma treated with anti-vascular endothelial growth factor-targeted agents","volume":"42","author":"Hwang","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.eururo.2022.05.029_b0130","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","article-title":"Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Gleeson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.05.029_b0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12885-016-2272-7","article-title":"Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report","volume":"16","author":"Kamai","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2022.05.029_b0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12894-019-0484-2","article-title":"Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures","volume":"19","author":"Park","year":"2019","journal-title":"BMC Urol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2022.05.029_b0145","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","article-title":"Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer","volume":"38","author":"Srinivasan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.05.029_b0150","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.4143\/crt.2019.086","article-title":"Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients","volume":"51","author":"Choi","year":"2019","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.eururo.2022.05.029_b0155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2021.04.009","article-title":"Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma","volume":"151","author":"Carril-Ajuria","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2022.05.029_b0160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10689-020-00195-0","article-title":"Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy: a case report","volume":"20","author":"Iribe","year":"2021","journal-title":"Fam Cancer"},{"key":"10.1016\/j.eururo.2022.05.029_b0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.15586\/jkcvhl.2020.148","article-title":"A case of metastatic hereditary leiomyomatosis and renal cell cancer syndrome-associated renal cell carcinoma treated with a sequence of axitinib and nivolumab following cytoreductive nephrectomy","volume":"7","author":"Yonese","year":"2020","journal-title":"J Kidney Cancer VHL"},{"key":"10.1016\/j.eururo.2022.05.029_b0170","doi-asserted-by":"crossref","first-page":"789","DOI":"10.21037\/tau.2019.12.37","article-title":"The preliminary outcome of the combination of immunotherapy and targeted therapy after recurrence and metastasis for hereditary leiomyomatosis and renal cell cancer\u2014a case report","volume":"9","author":"Feng","year":"2020","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.eururo.2022.05.029_b0175","doi-asserted-by":"crossref","unstructured":"Lee CH, Voss MH, Carlo MI, et al. Phase II trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol. In press. https:\/\/doi.org\/10.1200\/JCO.21.01944.","DOI":"10.1200\/JCO.21.01944"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382202406X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382202406X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:30:01Z","timestamp":1778535001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382202406X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S030228382202406X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.05.029","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}